Trial Profile

A Phase 1, Single and Multiple Ascending Dose and Food Effect Study of NEU-411 Administered Orally to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Healthy Subjects

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 01 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

24 Mar 2025 Results published in the Neuron23 Media Release.
24 Mar 2025 According to a Neuron23 media release, the company plans to present Initial findings from this trial at the 2025 International Conference on Alzheimer's and Parkinson's Diseases (AD/PD™), taking place April 1-5 in Vienna. The Company plans to present full results from the study, including modulation of phosphorylated Rab10 and di-22:6-bis(monoacylglycerol)-phosphate (BMP), at a future conference.
12 Jun 2024 Status changed from recruiting to completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com